Tissue and Plasma Thioredoxin Reductase Expressions in Patients with Glioblastoma Multiforme

Rahsan Kemerdere; Tibet Kacira; Hakan Hanimoglu; Mine Kucur; Taner Tanriverdi; Bulent Canbaz

doi:10.1055/s-0032-1333422

Journal of Neurological Surgery Part A: Central European Neurosurgery, Table of Contents

J Neurol Surg A Cent Eur Neurosurg 2013; 74(04): 234-238
DOI: 10.1055/s-0032-1333422

Original Article

Georg Thieme Verlag KG Stuttgart · New York

Tissue and Plasma Thioredoxin Reductase Expressions in Patients with Glioblastoma Multiforme

Authors

Rahsan Kemerdere

¹Department of Neurosurgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
Tibet Kacira

²Department of Neurosurgery, Acibadem Hospital Group, Istanbul, Turkey
Hakan Hanimoglu

³Department of Neurosurgery, Medical Faculty, Bezmi Alem Vakif University, Istanbul, Turkey
Mine Kucur

⁴Department of Biochemistry, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
Taner Tanriverdi

¹Department of Neurosurgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
Bulent Canbaz

¹Department of Neurosurgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

Abstract

Background and Study Aims Thioredoxin reductase (TrxR) is a redox protein that is considered to play a role in tumor progression. The purpose of this study was to assess the expression of TrxR in blood and tumor samples of glioblastoma multiforme (GBM) patients.

Patients TrxR levels were evaluated in blood and GBM tissues extracted from 27 patients, in normal brain tissues of 12 autopsy cases, and in blood samples of 12 healthy subjects. The results were compared between tumor and control groups.

Results The mean level of TrxR in GBM tissues (74.5 ± 14.9 U/g wet tissue) was remarkably higher than in normal brain tissues (14.8 ± 3.4 U/g wet tissue). The mean TrxR levels in blood were significantly higher in GBM patients (296.3 ± 43.6 U/mL) than in the controls (203.0 ± 11.3 U/mL).

Conclusions These findings suggest that high levels of TrxR may be related to progression of GBM.

Keywords

brain tumors - glioblastoma multiforme - thioredoxin reductase

Full Text

References

References
1 Louis DN, Ohgaki H, Wiestler OD , et al. The 2007 WHO Classification of Tumors of the Central Nervous System. Lyon, France: IARC Press; 2007
2 CBTRUS. 2008 statistical report: primary brain tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States, 2000–2004. Available at: http://www.cbtrus.org/reports/2007-2008/2007report.pdf . Accessed April 2012
3 Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507
4 Saether CA, Torsteinsen M, Torp SH , et al. Did survival improve after the implementation of intraoperative neuronavigation and 3D ultrasound in glioblastoma surgery? A retrospective analysis of 192 primary operations. J Neurol Surg A Cent Eur Neurosurg 2012; 73: 73-78
5 Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin 2007; 25: 867-890 , vii
6 Wrensch M, Wiencke JK, Wiemels J , et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 2006; 66: 4531-4541
7 Atukeren P, Kemerdere R, Kacira T , et al. Expressions of some vital molecules: glioblastoma multiforme versus normal tissues. Neurol Res 2010; 32: 492-501
8 Vitolo D, Paradiso P, Uccini S, Ruco LP, Baroni CD. Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology 1996; 28: 521-528
9 Chen TC, Hinton DR, Apuzzo MLJ, Hofman FM. Differential effects of tumor necrosis factor-alpha on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas. Neurosurgery 1993; 32: 85-94
10 Arnér ESJ, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 2006; 16: 420-426
11 Söderberg A, Sahaf B, Rosén A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res 2000; 60: 2281-2289
12 Powis G, Kirkpatrick DL, Angulo M, Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 1998; 111-112: 23-34
13 Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002; 62: 5089-5095
14 Kakolyris S, Giatromanolaki A, Koukourakis M , et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001; 7: 3087-3091
15 Choi JH, Kim TN, Kim S , et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 2002; 22: 3331-3335
16 Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 2005; 4: 6-13
17 Ford JM, Seiferheld W, Alger JR , et al. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2007; 69: 831-838
18 Ahmadi R, Urig S, Hartmann M , et al. Antiglioma activity of 2,2′:6′,2″-terpyridineplatinum(II) complexes in a rat model—effects on cellular redox metabolism. Free Radic Biol Med 2006; 40: 763-778
19 Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001; 41: 261-295
20 Nishinaka Y, Nakamura H, Masutani H, Yodoi J. Redox control of cellular function by thioredoxin; a new therapeutic direction in host defence. Arch Immunol Ther Exp (Warsz) 2001; 49: 285-292
21 Smart DK, Ortiz KL, Mattson D , et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 2004; 64: 6716-6724
22 Thelander L. Thioredoxin reductase. Characterization of a homogenous preparation from Escherichia coli B. J Biol Chem 1967; 242: 852-859
23 Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem 1997; 272: 30615-30618
24 Saitoh M, Nishitoh H, Fujii M , et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17: 2596-2606
25 Yokomizo A, Ono M, Nanri H , et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995; 55: 4293-4296
26 Raffel J, Bhattacharyya AK, Gallegos A , et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003; 142: 46-51
27 Järvelä S, Bragge H, Paunu N , et al. Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. J Neurooncol 2006; 77: 131-140
28 Haapasalo H, Kyläniemi M, Paunul N, Kinnula VL, Soini Y. Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol 2003; 13: 155-164
29 Furnari FB, Fenton T, Bachoo RM , et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-2710
30 Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets 2007; 11: 473-496
31 Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin 2007; 25: 1111-1139 , x
32 Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 2007; 110: 13-24